3.6 +/- 2.1
0.36 +/- 0.15
2.91 +/- 0.25BIOD-125
6.8 +/- 2.9*
0.50 +/- 0.19
3.08 +/- 0.26-- 100 mm Visual Analog Scale: 0=no discomfort, 100=worst possible discomfort
-- Absolute Severity Scale: 0=None, 1=Mild, 2=Moderate, 3=Severe
-- Relative Severity (compared to usual meal-time injections): 1=Much less, 2=Less, 3=Equal, 4=Increased, 5=Greatly increased
* p<0.05 vs. Humalog®Biodel's senior management will host a conference call to discuss the results and provide an update on the Company's progress.
April 16, 2012 schedule:8:15 am EDT:
Conference call participants should dial:+1 ( 877 ) 303 – 8028 (United States) or+1 ( 760 ) 536 – 5167 (International)8:30 am EDT:
Conference call beginsInterested parties may access a live audio webcast of the conference call in the investor section of Biodel's website at www.biodel.com. The audio webcast will be archived and available for replay through the website.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. We develop our product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. For further information regarding Biodel, please visit the company's website at www.biodel.com.Safe-Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements about future activities related to the clinical development plans for the company's drug candid
|SOURCE Biodel Inc.|
Copyright©2010 PR Newswire.
All rights reserved